{"product_id":"colivelin-10mg-vial","title":"Colivelin 10mg vial","description":"\u003cp data-end=\"697\" data-start=\"104\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003e                                             \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003eFOR HUMAN \u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003e\u003cstrong\u003eCONSUMPTION\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-end=\"697\" data-start=\"104\"\u003e\u003cstrong data-end=\"117\" data-start=\"104\"\u003eColivelin\u003c\/strong\u003e is best viewed as an \u003cstrong data-end=\"189\" data-start=\"139\"\u003einvestigational hybrid neuroprotective peptide\u003c\/strong\u003e, not a proven therapeutic or consumer nootropic \/ anti-aging peptide. It was designed by combining \u003cstrong data-end=\"299\" data-start=\"289\"\u003eADNF-9\u003c\/strong\u003e with a potent \u003cstrong data-end=\"336\" data-start=\"314\"\u003ehumanin derivative\u003c\/strong\u003e, with the goal of producing stronger neuroprotection than humanin-family peptides alone. The strongest evidence is still \u003cstrong data-end=\"473\" data-start=\"458\"\u003epreclinical\u003c\/strong\u003e, especially in \u003cstrong data-end=\"611\" data-start=\"489\"\u003eAlzheimer’s-disease-related models, ischemic injury, alcohol-induced neurotoxicity, and other neuronal-stress settings\u003c\/strong\u003e. Human efficacy evidence is essentially absent. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-end=\"754\" data-start=\"699\" data-section-id=\"o991e0\"\u003eAdditional benefits of colivelin under investigation\u003c\/h2\u003e\n\u003cdiv class=\"TyagGW_tableContainer\"\u003e\n\u003cdiv class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"2490\" data-start=\"756\"\u003e\n\u003cthead data-end=\"779\" data-start=\"756\"\u003e\n\u003ctr data-end=\"779\" data-start=\"756\"\u003e\n\u003cth class=\"\" data-col-size=\"md\" data-end=\"766\" data-start=\"756\"\u003eBenefit\u003c\/th\u003e\n\u003cth class=\"\" data-col-size=\"xl\" data-end=\"779\" data-start=\"766\"\u003eTake-away\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"2490\" data-start=\"790\"\u003e\n\u003ctr data-end=\"1052\" data-start=\"790\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"841\" data-start=\"790\"\u003e1. Alzheimer’s \/ amyloid-related neuroprotection\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1052\" data-start=\"841\"\u003eThis is the clearest use case. Colivelin showed strong protection against amyloid-related toxicity and improved memory in AD-model animals, but this remains preclinical. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1293\" data-start=\"1053\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1092\" data-start=\"1053\"\u003e2. Potentiated humanin-like activity\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1293\" data-start=\"1092\"\u003eColivelin was specifically created to be more potent than humanin derivatives alone, and early work reported activity at extremely low concentrations in vitro. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1484\" data-start=\"1294\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1324\" data-start=\"1294\"\u003e3. Ischemic neuroprotection\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1484\" data-start=\"1324\"\u003eAnimal work suggests protection of neurons and axons after ischemic injury, with anti-apoptotic signaling involvement. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1674\" data-start=\"1485\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1531\" data-start=\"1485\"\u003e4. Alcohol-related neurotoxicity protection\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1674\" data-start=\"1531\"\u003eColivelin reduced alcohol-induced apoptosis in neuronal models and in a fetal alcohol exposure model. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1862\" data-start=\"1675\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1714\" data-start=\"1675\"\u003e5. JAK2\/STAT3 and survival signaling\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1862\" data-start=\"1714\"\u003eA major mechanistic theme is activation of pro-survival pathways associated with humanin-family signaling. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2094\" data-start=\"1863\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1911\" data-start=\"1863\"\u003e6. CNS delivery interest via intranasal route\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2094\" data-start=\"1911\"\u003eIntranasal administration improved memory in AD-model mice and reached the CNS in preclinical work, which is a notable translational feature. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2310\" data-start=\"2095\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2147\" data-start=\"2095\"\u003e7. Broad neurotrophic \/ anti-apoptotic reputation\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2310\" data-start=\"2147\"\u003eReviews describe it as a promising neurotrophic peptide, but that reputation is driven mainly by cell and animal studies. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2490\" data-start=\"2311\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2361\" data-start=\"2311\"\u003e8. Not a proven human neurodegenerative therapy\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2490\" data-start=\"2361\"\u003eThe evidence base is overwhelmingly preclinical, with no established clinical efficacy. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003ch2 data-end=\"2527\" data-start=\"2492\" data-section-id=\"aq0rfb\"\u003e2. Molecular mechanism of action\u003c\/h2\u003e\n\u003ch3 data-end=\"2562\" data-start=\"2529\" data-section-id=\"jvsoby\"\u003e2.1 Receptor pharmacodynamics\u003c\/h3\u003e\n\u003cp data-end=\"2991\" data-start=\"2564\"\u003eColivelin does \u003cstrong data-end=\"2586\" data-start=\"2579\"\u003enot\u003c\/strong\u003e behave like a conventional small-molecule CNS drug. It is a \u003cstrong data-end=\"2665\" data-start=\"2647\"\u003ehybrid peptide\u003c\/strong\u003e built from \u003cstrong data-end=\"2687\" data-start=\"2677\"\u003eADNF-9\u003c\/strong\u003e and a potent \u003cstrong data-end=\"2719\" data-start=\"2701\"\u003ehumanin analog\u003c\/strong\u003e, intended to combine complementary neuroprotective properties. The literature ties its action mainly to \u003cstrong data-end=\"2871\" data-start=\"2824\"\u003ehumanin-related receptor\/survival signaling\u003c\/strong\u003e, especially \u003cstrong data-end=\"2898\" data-start=\"2884\"\u003eJAK2\/STAT3\u003c\/strong\u003e, rather than to one clean classic drug-receptor model. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-end=\"3019\" data-start=\"2993\" data-section-id=\"1c3fl0f\"\u003e2.2 Downstream biology\u003c\/h3\u003e\n\u003cdiv class=\"TyagGW_tableContainer\"\u003e\n\u003cdiv class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"3699\" data-start=\"3021\"\u003e\n\u003cthead data-end=\"3071\" data-start=\"3021\"\u003e\n\u003ctr data-end=\"3071\" data-start=\"3021\"\u003e\n\u003cth class=\"\" data-col-size=\"sm\" data-end=\"3039\" data-start=\"3021\"\u003ePathway \/ theme\u003c\/th\u003e\n\u003cth class=\"\" data-col-size=\"md\" data-end=\"3060\" data-start=\"3039\"\u003eFunctional outcome\u003c\/th\u003e\n\u003cth class=\"\" data-col-size=\"md\" data-end=\"3071\" data-start=\"3060\"\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"3699\" data-start=\"3086\"\u003e\n\u003ctr data-end=\"3242\" data-start=\"3086\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3118\" data-start=\"3086\"\u003eJAK2\/STAT3 survival signaling\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3161\" data-start=\"3118\"\u003eAnti-apoptotic \/ neuroprotective effects\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3242\" data-start=\"3161\"\u003eAD-related and neuronal-injury models \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3397\" data-start=\"3243\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3275\" data-start=\"3243\"\u003eHumanin-family cytoprotection\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3329\" data-start=\"3275\"\u003eResistance to amyloid and familial AD-gene toxicity\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3397\" data-start=\"3329\"\u003eNeurodegeneration models \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3545\" data-start=\"3398\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3425\" data-start=\"3398\"\u003eAnti-apoptotic signaling\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3475\" data-start=\"3425\"\u003eReduced neuronal death in toxic-stress settings\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3545\" data-start=\"3475\"\u003eAlcohol, ischemia, amyloid \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3699\" data-start=\"3546\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3569\" data-start=\"3546\"\u003eNeurotrophic support\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3631\" data-start=\"3569\"\u003ePreservation of neurons \/ axons and memory-related function\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3699\" data-start=\"3631\"\u003ePreclinical CNS research \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cp data-end=\"3857\" data-start=\"3701\"\u003eThese mechanisms are biologically compelling, but they still do \u003cstrong data-end=\"3772\" data-start=\"3765\"\u003enot\u003c\/strong\u003e establish strong clinical benefit in humans. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-end=\"3881\" data-start=\"3859\" data-section-id=\"b8x6nr\"\u003e3. Pharmacokinetics\u003c\/h2\u003e\n\u003cp data-end=\"4245\" data-start=\"3883\"\u003e\u003cstrong data-end=\"3902\" data-start=\"3883\"\u003eRoutes studied:\u003c\/strong\u003e mostly experimental administration in animals, including \u003cstrong data-end=\"3983\" data-start=\"3960\"\u003eintranasal delivery\u003c\/strong\u003e. The intranasal work is one of the more interesting translational aspects, because it suggests a less invasive way to reach the CNS. But this remains a \u003cstrong data-end=\"4166\" data-start=\"4136\"\u003epreclinical delivery story\u003c\/strong\u003e, not an established clinical platform. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-end=\"4287\" data-start=\"4247\" data-section-id=\"we631\"\u003e4. Pre-clinical and clinical evidence\u003c\/h2\u003e\n\u003ch3 data-end=\"4323\" data-start=\"4289\" data-section-id=\"t6khxa\"\u003e4.1 Alzheimer’s disease models\u003c\/h3\u003e\n\u003cp data-end=\"4722\" data-start=\"4325\"\u003eThis is the \u003cstrong data-end=\"4361\" data-start=\"4337\"\u003ebest-supported niche\u003c\/strong\u003e. Colivelin suppressed neuronal death induced by amyloid and familial-AD-related insults in vitro, and later animal studies found \u003cstrong data-end=\"4522\" data-start=\"4491\"\u003eimproved memory performance\u003c\/strong\u003e in AD-model mice. That is enough to explain why colivelin is often discussed as an anti-AD peptide, but it is still \u003cstrong data-end=\"4664\" data-start=\"4639\"\u003eanimal-model evidence\u003c\/strong\u003e, not human proof. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-end=\"4747\" data-start=\"4724\" data-section-id=\"1ada6oe\"\u003e4.2 Ischemic injury\u003c\/h3\u003e\n\u003cp data-end=\"4994\" data-start=\"4749\"\u003eA 2019 study reported that colivelin rescued ischemic neurons and axons and was associated with elevated anti-apoptotic gene expression. This supports a broader neuroprotection story beyond amyloid models. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-end=\"5033\" data-start=\"4996\" data-section-id=\"1e3u982\"\u003e4.3 Alcohol-induced neurotoxicity\u003c\/h3\u003e\n\u003cp data-end=\"5320\" data-start=\"5035\"\u003eColivelin also showed protection against alcohol-induced neuronal apoptosis in both primary cortical neurons and a mouse fetal alcohol exposure model. That widens its preclinical neuroprotective profile, though still without clinical validation. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-end=\"5344\" data-start=\"5322\" data-section-id=\"cnwh1g\"\u003e4.4 Human evidence\u003c\/h3\u003e\n\u003cp data-end=\"5632\" data-start=\"5346\"\u003eThis is the weak point. I did \u003cstrong data-end=\"5383\" data-start=\"5376\"\u003enot\u003c\/strong\u003e find evidence of established therapeutic human clinical trials showing efficacy for colivelin. The literature is dominated by \u003cstrong data-end=\"5555\" data-start=\"5510\"\u003ecell studies, animal studies, and reviews\u003c\/strong\u003e. That absence is a major limitation. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-end=\"5667\" data-start=\"5634\" data-section-id=\"1uuy0po\"\u003e5. Emerging clinical interests\u003c\/h2\u003e\n\u003cdiv class=\"TyagGW_tableContainer\"\u003e\n\u003cdiv class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"6319\" data-start=\"5669\"\u003e\n\u003cthead data-end=\"5699\" data-start=\"5669\"\u003e\n\u003ctr data-end=\"5699\" data-start=\"5669\"\u003e\n\u003cth class=\"\" data-col-size=\"md\" data-end=\"5677\" data-start=\"5669\"\u003eField\u003c\/th\u003e\n\u003cth class=\"\" data-col-size=\"md\" data-end=\"5689\" data-start=\"5677\"\u003eRationale\u003c\/th\u003e\n\u003cth class=\"\" data-col-size=\"md\" data-end=\"5699\" data-start=\"5689\"\u003eStatus\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"6319\" data-start=\"5714\"\u003e\n\u003ctr data-end=\"5864\" data-start=\"5714\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5759\" data-start=\"5714\"\u003eAlzheimer’s disease \/ cognitive impairment\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5803\" data-start=\"5759\"\u003eStrongest historical development interest\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5864\" data-start=\"5803\"\u003ePreclinical-heavy \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6001\" data-start=\"5865\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5889\" data-start=\"5865\"\u003eIschemic brain injury\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5934\" data-start=\"5889\"\u003eAnti-apoptotic and axon-protective effects\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"6001\" data-start=\"5934\"\u003eExploratory preclinical \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6172\" data-start=\"6002\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"6050\" data-start=\"6002\"\u003eDevelopmental \/ alcohol-related neurotoxicity\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"6105\" data-start=\"6050\"\u003eProtection against apoptosis in fetal alcohol models\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"6172\" data-start=\"6105\"\u003eExploratory preclinical \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6319\" data-start=\"6173\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"6199\" data-start=\"6173\"\u003eBroad neurodegeneration\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"6241\" data-start=\"6199\"\u003eHumanin-family \/ neurotrophic rationale\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"6319\" data-start=\"6241\"\u003ePlausible, but unproven clinically \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003ch2 data-end=\"6350\" data-start=\"6321\" data-section-id=\"7gr288\"\u003e6. Safety and tolerability\u003c\/h2\u003e\n\u003cp data-end=\"6693\" data-start=\"6352\"\u003eThere is \u003cstrong data-end=\"6396\" data-start=\"6361\"\u003eno mature human safety database\u003c\/strong\u003e for colivelin comparable to an approved drug. The peptide appears workable in animal studies, but that is not enough to establish human short-term or long-term safety. The best overall safety framing is therefore \u003cstrong data-end=\"6652\" data-start=\"6610\"\u003einsufficiently characterized in humans\u003c\/strong\u003e. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-end=\"6731\" data-start=\"6695\" data-section-id=\"fttgrx\"\u003e7. Contraindications and cautions\u003c\/h2\u003e\n\u003cp data-end=\"6756\" data-start=\"6733\"\u003eUse extra caution with:\u003c\/p\u003e\n\u003cul data-end=\"7409\" data-start=\"6758\"\u003e\n\u003cli data-end=\"6941\" data-start=\"6758\" data-section-id=\"1creixa\"\u003e\n\u003cstrong data-end=\"6841\" data-start=\"6760\"\u003eany claim that colivelin is a proven Alzheimer’s or neuroregenerative therapy\u003c\/strong\u003e, because the evidence remains overwhelmingly preclinical. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7108\" data-start=\"6942\" data-section-id=\"1moj5sf\"\u003e\n\u003cstrong data-end=\"6994\" data-start=\"6944\"\u003eself-experimentation \/ gray-market peptide use\u003c\/strong\u003e, because formal human dosing, efficacy, and safety are not established. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7282\" data-start=\"7109\" data-section-id=\"29slfp\"\u003e\n\u003cstrong data-end=\"7183\" data-start=\"7111\"\u003eassuming intranasal animal success will translate directly to humans\u003c\/strong\u003e, because that step has not been demonstrated clinically. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7409\" data-start=\"7283\" data-section-id=\"f073hk\"\u003e\n\u003cstrong data-end=\"7323\" data-start=\"7285\"\u003ereplacing standard neurologic care\u003c\/strong\u003e, because colivelin remains investigational. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2 data-end=\"7445\" data-start=\"7411\" data-section-id=\"o35cra\"\u003e8. Comparative practical matrix\u003c\/h2\u003e\n\u003cdiv class=\"TyagGW_tableContainer\"\u003e\n\u003cdiv class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"8000\" data-start=\"7447\"\u003e\n\u003cthead data-end=\"7470\" data-start=\"7447\"\u003e\n\u003ctr data-end=\"7470\" data-start=\"7447\"\u003e\n\u003cth class=\"\" data-col-size=\"sm\" data-end=\"7457\" data-start=\"7447\"\u003eFeature\u003c\/th\u003e\n\u003cth class=\"\" data-col-size=\"md\" data-end=\"7470\" data-start=\"7457\"\u003eColivelin\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"8000\" data-start=\"7481\"\u003e\n\u003ctr data-end=\"7547\" data-start=\"7481\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7497\" data-start=\"7481\"\u003eMain strength\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"7547\" data-start=\"7497\"\u003eInvestigational hybrid neuroprotective peptide\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7625\" data-start=\"7548\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7574\" data-start=\"7548\"\u003eBest-supported use case\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"7625\" data-start=\"7574\"\u003ePreclinical Alzheimer’s-related neuroprotection\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7668\" data-start=\"7626\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7652\" data-start=\"7626\"\u003eClinical evidence depth\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"7668\" data-start=\"7652\"\u003eVery limited\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7729\" data-start=\"7669\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7687\" data-start=\"7669\"\u003eCore limitation\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"7729\" data-start=\"7687\"\u003eMostly animal and mechanistic evidence\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7829\" data-start=\"7730\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7754\" data-start=\"7730\"\u003eMain mechanism themes\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"7829\" data-start=\"7754\"\u003eHumanin-derived survival signaling, JAK2\/STAT3, anti-apoptotic activity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7888\" data-start=\"7830\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7850\" data-start=\"7830\"\u003eDelivery interest\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"7888\" data-start=\"7850\"\u003eIntranasal CNS delivery in animals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7932\" data-start=\"7889\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7911\" data-start=\"7889\"\u003eMain safety concern\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"7932\" data-start=\"7911\"\u003eSparse human data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"8000\" data-start=\"7933\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7958\" data-start=\"7933\"\u003eBest practical framing\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"8000\" data-start=\"7958\"\u003eResearch peptide, not a proven therapy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003ch2 data-end=\"8028\" data-start=\"8002\" data-section-id=\"n437ah\"\u003e9. Regulatory landscape\u003c\/h2\u003e\n\u003cp data-end=\"8252\" data-start=\"8030\"\u003eColivelin is best understood as a \u003cstrong data-end=\"8084\" data-start=\"8064\"\u003eresearch peptide\u003c\/strong\u003e, not an approved drug or validated supplement. The literature supports serious biologic interest, but not routine clinical use. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-end=\"8278\" data-start=\"8254\" data-section-id=\"1fjxpfd\"\u003e10. Future directions\u003c\/h2\u003e\n\u003cp data-end=\"8317\" data-start=\"8280\"\u003eThe most useful future work would be:\u003c\/p\u003e\n\u003cul data-end=\"8684\" data-start=\"8319\"\u003e\n\u003cli data-end=\"8373\" data-start=\"8319\" data-section-id=\"y9xl1f\"\u003ereal \u003cstrong data-end=\"8370\" data-start=\"8326\"\u003ehuman pharmacokinetic and safety studies\u003c\/strong\u003e,\u003c\/li\u003e\n\u003cli data-end=\"8451\" data-start=\"8374\" data-section-id=\"1x5llnd\"\u003eindication-specific trials in \u003cstrong data-end=\"8448\" data-start=\"8406\"\u003eAlzheimer’s disease or ischemic injury\u003c\/strong\u003e,\u003c\/li\u003e\n\u003cli data-end=\"8513\" data-start=\"8452\" data-section-id=\"1w5zks4\"\u003ebetter confirmation of \u003cstrong data-end=\"8500\" data-start=\"8477\"\u003eintranasal delivery\u003c\/strong\u003e in humans,\u003c\/li\u003e\n\u003cli data-end=\"8684\" data-start=\"8514\" data-section-id=\"ketzln\"\u003eand clearer mechanistic separation of what comes from the \u003cstrong data-end=\"8593\" data-start=\"8574\"\u003ehumanin-derived\u003c\/strong\u003e versus \u003cstrong data-end=\"8619\" data-start=\"8601\"\u003eADNF-9-derived\u003c\/strong\u003e portions of the peptide. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2 data-end=\"8710\" data-start=\"8686\" data-section-id=\"1uk6y2z\"\u003eBest balanced summary\u003c\/h2\u003e\n\u003cp data-end=\"9225\" data-start=\"8712\"\u003e\u003cstrong data-end=\"9185\" data-start=\"8712\"\u003eColivelin is best viewed as a hybrid humanin\/ADNF-derived investigational peptide with substantial preclinical evidence for neuroprotective and anti-apoptotic effects, especially in Alzheimer’s-related, ischemic, and toxic neuronal-injury models. Its biology is credible and in some studies highly potent, but the translation gap is large: human efficacy evidence is lacking, safety is not well characterized clinically, and there is no established approved indication.\u003c\/strong\u003e\u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 data-end=\"9249\" data-start=\"9227\" data-section-id=\"xxd8hg\"\u003eSelected references\u003c\/h2\u003e\n\u003cul data-end=\"10572\" data-start=\"9251\"\u003e\n\u003cli data-end=\"9518\" data-start=\"9251\" data-section-id=\"19tcbwa\"\u003e\n\u003cstrong data-end=\"9272\" data-start=\"9253\"\u003eChiba T, et al.\u003c\/strong\u003e \u003cem data-end=\"9375\" data-start=\"9273\"\u003eCharacterization of Colivelin-Mediated Neuroprotection Against Alzheimer’s Disease-Relevant Insults.\u003c\/em\u003e Foundational paper describing colivelin as a hybrid peptide and showing very potent neuroprotection. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9791\" data-start=\"9519\" data-section-id=\"10je049\"\u003e\n\u003cstrong data-end=\"9549\" data-start=\"9521\"\u003eMatsuoka M, Hashimoto Y.\u003c\/strong\u003e \u003cem data-end=\"9669\" data-start=\"9550\"\u003eHumanin and colivelin: neuronal-death-suppressing peptides for Alzheimer’s disease and amyotrophic lateral sclerosis.\u003c\/em\u003e Good review-level framing for humanin-family biology and colivelin’s rationale. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"10006\" data-start=\"9792\" data-section-id=\"msyh3k\"\u003e\n\u003cstrong data-end=\"9814\" data-start=\"9794\"\u003eYamada M, et al.\u003c\/strong\u003e \u003cem data-end=\"9904\" data-start=\"9815\"\u003eNasal Colivelin Treatment Ameliorates Memory Impairment Related to Alzheimer’s Disease.\u003c\/em\u003eBest source for intranasal delivery and animal memory data. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"10213\" data-start=\"10007\" data-section-id=\"zpnxhh\"\u003e\n\u003cstrong data-end=\"10026\" data-start=\"10009\"\u003eWu MN, et al.\u003c\/strong\u003e \u003cem data-end=\"10135\" data-start=\"10027\"\u003eColivelin Ameliorates Amyloid β Peptide-Induced Memory Impairment in a Mouse Model of Alzheimer’s Disease.\u003c\/em\u003e Good later in vivo AD-model source. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"10365\" data-start=\"10214\" data-section-id=\"utna9\"\u003e\n\u003cstrong data-end=\"10234\" data-start=\"10216\"\u003eZhao H, et al.\u003c\/strong\u003e \u003cem data-end=\"10281\" data-start=\"10235\"\u003eColivelin Rescues Ischemic Neuron and Axons.\u003c\/em\u003e Best source for ischemic neuroprotection. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"10572\" data-start=\"10366\" data-section-id=\"1fysknz\"\u003e\n\u003cstrong data-end=\"10386\" data-start=\"10368\"\u003eSari Y, et al.\u003c\/strong\u003e \u003cem data-end=\"10483\" data-start=\"10387\"\u003eA novel peptide, colivelin, prevents alcohol-induced apoptosis in fetal brain of C57BL\/6 mice.\u003c\/em\u003e Best source for the alcohol-neurotoxicity angle.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":55801327911176,"sku":null,"price":200.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0937\/9053\/5944\/files\/colivelin_10mg.png?v=1775241411","url":"https:\/\/rcpeptides.com\/products\/colivelin-10mg-vial","provider":"RCpeptides","version":"1.0","type":"link"}